Expanded Facility in Fleurus, Belgium to be leading player in supply of
Glucotrace(R) for growing market
OTTAWA, March 1 /CNW/ - MDS Nordion, a leading global provider of medical
isotopes and radiopharmaceuticals for molecular imaging, is investing U.S.
$5.8 million / (euro) 4.5 million to expand its production facility in
Fleurus, Belgium to meet the growing demand for a medical imaging agent used
in cancer diagnosis and treatment. The agent, Fluorine-18 Fludeoxyglucose or
FDG, is marketed and distributed by MDS Nordion under the name Glucotrace(R).
Glucotrace(R) is used in a highly sensitive medical imaging technique called
PET or Positron Emission Tomography. As cancer rates continue to rise in
Europe, the use of PET is increasing to diagnose cancer and monitor patient
progress while in treatment.
Glucotrace(R) is a time-sensitive diagnostic pharmaceutical with a
limited lifespan. As a result, it is critical to have the ability to reliably
supply Glucotrace(R) to hospitals and clinical sites on time. With this
expansion, MDS Nordion will be able to serve more customers within France and
the Benelux Economic Union (Belgium, Netherlands and Luxembourg).
"The new production facility will give MDS Nordion the ability to meet
increased demand from our current customers as well as extend our market reach
to new customers," said Steve West, President of MDS Nordion. "We are
committed to providing a reliable supply of Glucotrace(R) to the medical
imaging community in Europe."
Through this investment and capital upgrade, MDS Nordion will build a
larger production centre for Glucotrace(R) within its existing facilities in
Fleurus. The investment will also optimize MDS Nordion's current resources
including a higher capacity cyclotron to produce FDG.
Presently, MDS Nordion produces Glucotrace(R) as part of a joint venture
with the University of Liège (ULG) about 80 kilometres west of Fleurus. The
new MDS Nordion facility in Fleurus, combined with the existing site at ULG,
will greatly increase production capacity for Europe as well as provide the
necessary manufacturing and supply flexibility to serve growing market demand.
First production of Glucotrace(R) from the new facility in Fleurus is
expected to begin in mid-2008. Glucotrace(R) is approved for sale across
About MDS Nordion
MDS Nordion (www.mds.nordion.com) is a world leader in medical isotopes,
radiation and related technologies. It is a division of MDS Inc.
(TSX:MDS)(NYSE: MDZ). MDS Inc. is a global life sciences company that provides
market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS has more
than 5,600 highly skilled people in 28 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information:
For further information: Media Inquiries, Olivia Nixon, MDS Nordion,
(613) 592-2790 ext. 2558, (613) 724-1767 (Mobile), email@example.com;
Investor Inquiries, Sharon Mathers, Vice-President, Investor Relations and
External Communications, (416) 675-6777 ext. 34721, firstname.lastname@example.org